Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer?

Ähnliche Einträge

• Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach
  von: Jassem, Jacek
  Veröffentlicht: (2019)
• Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
  von: Lemmon, Christopher, et al.
  Veröffentlicht: (2020)
• Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how?
  von: Bruno, Debora, et al.
  Veröffentlicht: (2019)
• Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor—resistant non-small cell lung cancer
  von: Jiang, Tao, et al.
  Veröffentlicht: (2014)
• Recent advances in the development of mutant-selective EGFR inhibitors for non-small cell lung cancer patients with EGFR-TKI resistance
  von: Luo, Yung-Hung, et al.
  Veröffentlicht: (2014)